+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Overactive Bladder Treatment Market - Global Forecast 2026-2032- Product Image
Overactive Bladder Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Overactive Bladder Treatment Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968613
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Overactive Bladder Treatment Market is projected to reach USD 4.37 Billion in 2026. It is expected to continue growing at a CAGR of 6.67%, reaching USD 6.45 Billion by 2032.

Overactive bladder treatment is a high-need segment of urology and continence care, focused on urgency, urinary frequency, nocturia, and urge urinary incontinence in the absence of infection or another clear pathology. Population studies consistently show that overactive bladder affects a meaningful share of adults, with the EPIC study estimating overall prevalence at about 11.8%, and burden rising with age. The condition affects quality of life, sleep, work productivity, fall risk in older adults, sexual health, mental well-being, and caregiver burden, making effective OAB therapy a priority for health systems, clinicians, payers, and life sciences stakeholders.

Current evidence-based care follows a stepped model supported by AUA/SUFU, EAU, and NICE guidance: behavioral therapy and bladder training, pelvic floor muscle therapy, pharmacologic treatment with antimuscarinic drugs or beta-3 adrenergic agonists, and advanced options such as intradetrusor botulinum toxin, percutaneous tibial nerve stimulation, and sacral neuromodulation. The strongest growth opportunities sit at the intersection of aging demographics, improved diagnosis, adherence-focused care, cognitive safety, patient-reported outcomes, and access to minimally invasive overactive bladder treatment.

Transformative Shifts in the OAB Treatment Landscape

The overactive bladder treatment landscape is shifting from short-term symptom suppression to individualized, long-term disease management. Clinicians are increasingly balancing efficacy with tolerability, cognitive safety, constipation risk, dry mouth, blood pressure considerations, polypharmacy, frailty, patient preference, and persistence on therapy. This is expanding the role of beta-3 adrenergic agonists and reinforcing the need for shared decision-making across first-, second-, and third-line OAB therapy.

A second major shift is the normalization of minimally invasive treatment earlier in the patient journey when oral therapy fails, is contraindicated, or is not tolerated. Neuromodulation, intradetrusor botulinum toxin, digital bladder diaries, remote symptom tracking, and pelvic floor rehabilitation are being integrated into multidisciplinary continence care models. For industry leaders, the landscape is no longer defined only by prescriptions; it is increasingly shaped by outcomes, persistence, device access, specialist capacity, patient education, reimbursement evidence, and payer acceptance of durable symptom control.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence overactive bladder care through digital symptom capture, automated bladder diary interpretation, patient phenotyping, and risk prediction. AI-enabled tools can help identify patterns in urgency episodes, nocturia, fluid intake, medication adherence, comorbidities, and treatment response, supporting more precise therapy selection and earlier escalation when conservative management is insufficient.

The cumulative impact will depend on clinical validation, bias mitigation, interoperability with electronic health records, and responsible use of sensitive urinary health data. In research and commercialization, AI can improve trial recruitment, real-world evidence generation, adverse-event monitoring, patient segmentation, and patient support programs. The highest-value applications will be those that demonstrate measurable improvement in adherence, symptom control, access, clinical workflow efficiency, and cost-effective overactive bladder management.

Key Regional Insights

Asia-Pacific is gaining importance as aging populations in Japan, China, South Korea, and Australia combine with rising urology awareness, expanding private healthcare access, and broader use of specialty clinics, while India and Southeast Asia show long-term potential as diagnosis rates, primary care referral pathways, and continence education improve. North America remains a leading region for overactive bladder treatment because of high specialist availability, FDA-cleared devices, broad use of prescription OAB medications, established use of botulinum toxin and neuromodulation, and mature payer pathways for advanced therapies.

Europe benefits from strong guideline adoption, established continence services, and reimbursement scrutiny that favors therapies supported by durable outcomes, patient safety data, and health-economic evidence. Latin America is advancing through urban hospital networks in Brazil and Mexico, although affordability, uneven insurance coverage, and specialist access remain constraints. The Middle East, particularly Gulf markets, is investing in urology infrastructure, premium care, and hospital modernization, while Africa remains underpenetrated, with opportunity tied to workforce development, awareness, basic diagnostic capacity, women’s health integration, and access to essential continence care.

Key Group Insights

ASEAN markets are heterogeneous: Singapore and Malaysia show stronger private-sector adoption of overactive bladder medication, specialist consultation, and selected device-enabled therapies, while Indonesia, Vietnam, Thailand, and the Philippines offer scale as primary care recognition of urgency, nocturia, and urge urinary incontinence improves. The GCC is positioned for premium urology services, medical tourism, and device-enabled treatment adoption, supported by high healthcare spending, hospital modernization, and expanding specialist networks across Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman.

The European Union emphasizes clinical evidence, patient safety, post-market surveillance, and health technology assessment, making real-world outcomes essential for market access in overactive bladder treatment. BRICS countries create volume opportunity through large populations, urbanization, aging, and expanding specialist networks, but pricing, reimbursement, and local treatment pathways must be localized. G7 markets anchor innovation in beta-3 agonists, neuromodulation, botulinum toxin protocols, digital health, and evidence-based continence care. NATO is not a healthcare market bloc, but its member economies influence supply chain resilience, cybersecurity expectations, data protection practices, and medical technology standards relevant to connected OAB treatment platforms.

Key Country Insights

In the United States, overactive bladder treatment is shaped by AUA/SUFU guidance, broad drug availability, office-based procedures, established coding pathways, and strong medical technology adoption. Canada follows evidence-based care with provincial reimbursement variation, while Mexico and Brazil show demand growth through private hospitals, urban specialty care, and expanding urology access. The United Kingdom, Germany, France, Italy, and Spain benefit from established continence pathways, specialist referral systems, and guideline-driven care, although cost-effectiveness review, reimbursement rules, and waiting times influence therapy uptake; Russia remains a sizable but access-variable market, with adoption shaped by regional healthcare investment and availability of advanced therapies.

China and India represent major long-term opportunities due to population size, aging, urbanization, expanding hospital networks, and improving specialty care, but affordability, diagnosis gaps, rural access, and patient awareness remain central barriers. Japan has high awareness of urinary symptoms in older adults, established pharmacologic use, and strong relevance for therapies that support tolerability in aging patients. Australia combines guideline-driven care with access to specialist continence services, pelvic floor therapy, and advanced urology centers, while South Korea shows strong adoption potential through advanced hospitals, digital infrastructure, high technology acceptance, and an aging population.

Actionable Recommendations for Industry Leaders

Industry leaders should build overactive bladder strategies around the full care continuum, not a single intervention. This means supporting screening in primary care, digital bladder diaries, validated symptom scores, adherence programs, pelvic floor therapy referral pathways, patient education, and clear escalation criteria for botulinum toxin, tibial nerve stimulation, and sacral neuromodulation.

Commercial success will depend on proving patient-centered value. Organizations should invest in real-world evidence, comparative effectiveness data, long-term safety communication, payer-ready health economics, inclusive clinical research across older adults and patients with comorbidities, and care models that reduce discontinuation. AI and digital tools should be deployed only where they improve measurable outcomes, reduce friction for clinicians and patients, and meet privacy, cybersecurity, interoperability, and clinical validation standards.

Research Methodology

This executive summary is based on triangulation of publicly available clinical guidelines, regulatory information, peer-reviewed urology literature, epidemiology sources, payer considerations, and market access signals. Priority references include AUA/SUFU, EAU, NICE, FDA, EMA, national health agencies, and published evidence on behavioral therapy, antimuscarinics, beta-3 adrenergic agonists, botulinum toxin, tibial nerve stimulation, sacral neuromodulation, and patient-reported outcome measures.

Insights were developed by comparing disease burden, treatment pathways, regional healthcare infrastructure, reimbursement maturity, adoption barriers, technology readiness, and clinical practice patterns. No unverified market-size figures, market share estimates, or forecasts are used. Where regional or country outlooks are discussed, conclusions are grounded in observable drivers such as aging demographics, specialist availability, guideline adoption, regulatory access, reimbursement evidence, healthcare investment, and documented burden of urgency, nocturia, and urge urinary incontinence.

Conclusion

Overactive bladder treatment is evolving into a more personalized, outcomes-driven field. Behavioral care remains foundational, but sustained advancement is being driven by improved pharmacologic choice, greater use of minimally invasive therapies, digital symptom monitoring, and growing recognition of the burden of urgency, nocturia, urinary frequency, and urge urinary incontinence.

The most competitive organizations will combine clinical credibility with access strategy, real-world evidence, responsible digital innovation, and patient support. As healthcare systems prioritize value, safety, adherence, and quality of life, the strongest opportunities will come from solutions that improve diagnosis, persistence, tolerability, and durable symptom control across diverse patient populations and healthcare settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Overactive Bladder Treatment Market, by Product Type
7.1. Introduction
7.2. Anticholinergics
7.2.1. Extended Release
7.2.2. Immediate Release
7.3. Beta-3 Agonists
7.3.1. Mirabegron
7.3.2. Vibegron
7.4. Botulinum Toxin
7.4.1. Type A
7.4.2. Type B
7.5. Neuromodulation Devices
7.5.1. Percutaneous Tibial Nerve Stimulation
7.5.2. Sacral Neuromodulation
8. Overactive Bladder Treatment Market, by Therapeutic Class
8.1. Introduction
8.2. Non Pharmacological
8.2.1. Behavioral Therapy
8.2.2. Neuromodulation
8.2.3. Pelvic Floor Muscle Training
8.3. Pharmacological
9. Overactive Bladder Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Intravesical
9.4. Oral
9.5. Transcutaneous
10. Overactive Bladder Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Overactive Bladder Treatment Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Home Care
11.4. Hospital
12. Overactive Bladder Treatment Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Overactive Bladder Treatment Market, by Gender
13.1. Introduction
13.2. Female
13.3. Male
14. Overactive Bladder Treatment Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Overactive Bladder Treatment Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Overactive Bladder Treatment Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Advanz Pharma Corp. Limited
18.3. Alembic Pharmaceuticals Limited
18.4. Amneal Pharmaceuticals LLC
18.5. Astellas Pharma Inc.
18.6. Aurobindo Pharma Limited
18.7. Axonics, Inc.
18.8. Bayer AG
18.9. Cipla Limited
18.10. Cogentix Medical, Inc.
18.11. Dr. Reddy’s Laboratories Limited
18.12. Endo International plc
18.13. Hisamitsu Pharmaceutical Co., Inc.
18.14. Idorsia Ltd.
18.15. Johnson & Johnson
18.16. Laborie Medical Technologies Corp.
18.17. Lupin Limited
18.18. Macleods Pharmaceuticals Limited
18.19. Medtronic plc
18.20. Neuspera Medical, Inc.
18.21. Novartis AG
18.22. Pfizer Inc.
18.23. Sandoz AG
18.24. Sanofi S.A.
18.25. Sun Pharmaceutical Industries Limited
18.26. Teva Pharmaceutical Industries Ltd.
18.27. Uro Medical Corporation
18.28. Urovant Sciences Ltd.
18.29. Vensica Medical Ltd.
18.30. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL EXTENDED RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL EXTENDED RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL EXTENDED RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL BETA-3 AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BETA-3 AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BETA-3 AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MIRABEGRON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MIRABEGRON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MIRABEGRON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VIBEGRON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VIBEGRON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VIBEGRON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TYPE A MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TYPE A MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TYPE A MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TYPE B MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TYPE B MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TYPE B MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL NEUROMODULATION DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PERCUTANEOUS TIBIAL NERVE STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PERCUTANEOUS TIBIAL NERVE STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PERCUTANEOUS TIBIAL NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SACRAL NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SACRAL NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SACRAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NON PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL BEHAVIORAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PELVIC FLOOR MUSCLE TRAINING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PELVIC FLOOR MUSCLE TRAINING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PELVIC FLOOR MUSCLE TRAINING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAVESICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAVESICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAVESICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TRANSCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TRANSCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TRANSCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL FEMALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL FEMALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL FEMALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL MALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL MALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 146. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 148. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 149. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 151. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 152. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 153. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 154. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 158. EUROPE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 172. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 174. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 175. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 176. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 177. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 178. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 179. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 180. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 184. AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 189. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 190. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 191. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 192. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 193. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 194. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 196. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 198. ASEAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 199. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 201. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 202. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 203. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 204. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 205. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 206. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 207. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 211. GCC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 225. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 228. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 229. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 230. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 231. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 232. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 233. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 237. BRICS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 238. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 239. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 240. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 241. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 242. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 243. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 244. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 245. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 246. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 250. G7 OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 251. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 252. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 253. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 254. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 255. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 256. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 257. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 258. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 259. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 263. NATO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 264. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 278. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 280. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 281. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 282. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 283. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 284. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 285. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 286. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 290. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 291. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 293. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 294. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 295. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 296. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 297. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 298. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 299. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 303. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GENDER, 2017-2032 (USD MILLION)
TABLE 330. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 332. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2017-2032 (USD MILLION)
TABLE 333. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BETA-3 AGONISTS, 2017-2032 (USD MILLION)
TABLE 334. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTULINUM TOXIN, 2017-2032 (USD MILLION)
TABLE 335. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICES, 2017-2032 (USD MILLION)
TABLE 336. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPE

Companies Mentioned

  • AbbVie Inc.
  • Advanz Pharma Corp. Limited
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Axonics, Inc.
  • Bayer AG
  • Cipla Limited
  • Cogentix Medical, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Endo International plc
  • Hisamitsu Pharmaceutical Co., Inc.
  • Idorsia Ltd.
  • Johnson & Johnson
  • Laborie Medical Technologies Corp.
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Medtronic plc
  • Neuspera Medical, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Uro Medical Corporation
  • Urovant Sciences Ltd.
  • Vensica Medical Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.37 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.45 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Overactive Bladder Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapy, Disease Type, Route of Administration, End User - Product Image

Overactive Bladder Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapy, Disease Type, Route of Administration, End User

  • Report
  • 160 Pages
  • Global
From
Overactive Bladder Treatment Market Report 2026 - Product Image

Overactive Bladder Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
2025 Global Forecast for Overactive Bladder Treatment Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Overactive Bladder Treatment Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Pediatric Bladder Treatment Market Report 2026 - Product Image

Pediatric Bladder Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report - Product Image

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From

About the Overactive Bladder Drug Market

The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations. The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.